Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics, Inc. (CMPX)
Company Research
Source: GlobeNewswire
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the acceptance of an abstract for poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Poster Title: Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody Authors: Kris Sachsenmeier, Niharika Mettu, Martin Gutierrez, Jeffery Edenfield, Seth Rosen, Minal Barve, Karin Herrera, Natalie Warholic, Diana Albu, Alberto Visintin, Thomas Schuetz, Tanner Johanns Abstract Number: 679Date & Time: Friday, November 8, 2024, 9:00 AM – 7:00 PM CDTLocation: Exhibit Halls AB A copy of the presentation material
Show less
Read more
Impact Snapshot
Event Time:
CMPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMPX alerts
High impacting Compass Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CMPX
News
- Compass Therapeutics, Inc. (NASDAQ: CMPX) was upgraded by analysts at LADENBURG THALM/SH SH from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock.MarketBeat
- Compass Therapeutics to Participate in Upcoming Investor EventsGlobeNewswire
- Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX) [Yahoo! Finance]Yahoo! Finance
- Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswire
CMPX
Earnings
- 8/12/24 - In-Line
CMPX
Sec Filings
- 9/9/24 - Form EFFECT
- 8/30/24 - Form S-3
- 8/14/24 - Form 4
- CMPX's page on the SEC website